Activins are growth and differentiation factors which have been shown to have proliferative and antiproliferative actions in many tissues. In addition, they have been implicated in tumourigenesis in reproductive tissues. Although activin and inhibin are present in rat ventral prostate, inhibin , but not , subunit proteins have been detected in the human prostate epithelial tumour cell lines LNCaP, DU145 and PC3. With this absence of capacity to produce inhibins, the aims of this study were to determine the effect of activin A and B and follistatin on DNA synthesis by these human prostate tumour cell lines. The results demonstrate a differential response to exogenously added activin A and B on DNA synthesis in vitro by the tumour cell lines. The inhibitory effects were observed on LNCaP cells in the absence or presence of stimulation with 1 n 5 -dihydrotestosterone and on the androgen-independent DU145 cells, but not the PC3 cells. Activin A caused a dose-dependent inhibition of DNA synthesis and proliferation by LNCaP and androgen-independent DU145 cells which was maximal at 8 ng/ml. The effect of exogenously added activin A was completely reversed by follistatin, but not by inhibin A. The addition of human recombinant FS 288 alone (400 ng/ml) did not have any effect on DNA synthesis, whereas inhibin A alone (400 ng/ml) caused a significant inhibition of DNA synthesis. The capacity of all three cell lines to produce activins and follistatins was demonstrated by the expression of the mRNAs and confirmed by the localisation of immunoreactivity for these ligands to the cytoplasm of the tumour cells. The growth inhibitory response to activins A and B by LNCaP and DU145 cells, and the ability of follistatin to block these effects, suggest that the autocrine interactions between activins and follistatins have a role in the regulation of LNCaP and DU145 prostate tumour cell growth.
Introduction
The essential, but not exclusive, involvement of androgens in prostate cancer has implicated growth factors in the regulation of tumour cell growth (Steiner 1993) . Many peptide growth factors, including transforming growth factor-(TGF ), are potent regulators of cell proliferation and cell death, and may contribute to the neoplastic transformation of the normal cell. Activins are members of the TGF superfamily, and share a common subunit with inhibins. Activins are homo-or heterodimers of inhibin subunits ( A or B ), whereas inhibins are dimers of an and one of the two subunits (Mason et al. 1985) . A role for inhibins in tumour suppression was suggested by the generation of inhibin-deficient mice and the subsequent demonstration that both male and female animals develop gonadal tumours (Matzuk et al. 1992) . In contrast, increased serum inhibin immunoreactivity was reported in patients with granulosa cell tumours of the ovary (Healy et al. 1993) , and the role of inhibin as a tumour-suppressive gene in human cancer remains unknown.
Activin A has been shown to have proliferative and antiproliferative effects on rat thymocytes, spermatogonia, 3T3 cells and foetal testicular tissues (Hedger et al. 1989 , van-Dissel-Emiliani et al. 1989 , Mather et al. 1990 , Kaipia et al. 1994 . As the activin type II receptor gene is expressed in the rat prostate (Feng et al. 1993) , activins may be involved in prostate growth and development. We postulate that this growth factor has a role in maintaining the balance of cell growth in the prostate, and this is supported by the detection of inhibin A and B (but not ) subunit mRNA and activin receptor mRNA expression in the tumour cell lines DU145, PC3 and LNCaP (Batres et al. 1995 , Furst et al. 1995 . The absence of subunit results in a loss of the capacity to synthesise inhibins; the subunits can therefore only form activin ligands, activin A, B or AB. We have studied the action of activin A and B on DNA synthesis by three prostate tumour cell lines: the androgen-dependent LNCaP cells and the androgen-independent DU145 and PC3 cells. In addition, we studied both the colocalisation of activin A and follistatin to the cell lines using a specific antiserum, AS no. 64, which detects activin A and an antiserum that detects follistatin, AS no. 202, and the effect of follistatin alone and in combination with activin A on the tumour cells.
Methods

Human prostate epithelial tumour cell lines
Human prostate tumour cell lines LNCaP, DU145 and PC3 were obtained from American Type Culture Collection (Rockville, MD, USA). Cell lines were routinely cultured in Dulbecco's Modified Eagle's Medium (DMEM; Gibco, NY, USA) with 10% heat-inactivated FCS (PA Biologicals Co. Pty Ltd, NSW, Australia) and antibiotics (100 UI/ml penicillin and 10 µg/ml streptomycin; CSL Limited, Parkville, Vic, Australia) in 75 cm 2 culture flasks (Costar; Corning Costar Corp., Cambridge, MA, USA) at 37 C in a humidified atmosphere of 5% CO 2 in air. Cell lines were passaged twice weekly by trypsinisation. When used in test cultures, cells were plated to provide subconfluent monolayers before the addition of test substances.
Growth factors, steroids and other chemicals
Human recombinant activin A and human recombinant inhibin A were kindly provided by Biotech Australia Pty Ltd (East Roseville, NSW, Australia) and Prof. D M de Kretser (Institute of Reproduction and Development, Monash Medical Centre, Clayton, Vic, Australia), human recombinant activin B was a gift from Dr J Mather, Genentech Inc., USA. Human recombinant follistatin (FS288) was obtained from the National Hormone and Pituitary Program, Rockville, MD, USA. Activin A was stored in 0·1% trifluoroacetic acid/acetonitrile (TFN/ ACN) and freeze-dried; activin B was stored frozen at 70 C in Dulbecco's phosphate buffered saline (DPBS)+0·1% BSA; FS288 was stored in 50% glycerol at 20 C. All proteins were diluted or reconstituted in DMEM+5% charcoal-stripped FCS (CCS).
5 -Dihydrotestosterone (DHT; Sigma Chemical Co., St Louis, MO, USA) was dissolved in 100% ethanol and diluted to 1 m to provide a stock solution. DHT was used in cell cultures at 1 n in DMEM+5% CCS. CCS was obtained by treating FCS with dextran-coated charcoal to remove steroids as described by Darbre et al. (1983) . Tritiated thymidine ([ 3 H]thymidine) was purchased from DuPont, NEN Research Products, Boston, MA, USA.
Immunolocalisation studies Antibodies The antiserum AS no. 64 was raised against a bovine A subunit fusion protein (Forage et al. 1987) and human recombinant activin A in sheep. This antiserum has previously been used for the radioimmunoassay of activin A and has no cross-reactivity with Mullerian inhibiting substance and TGF and <3·3% cross-reactivity with human recombinant inhibin A (Robertson et al. 1992) . The radioimmunoassay using AS no. 64 has been used previously to purify dimeric activin A to homogeneity from ovine amniotic fluid (de Kretser et al. 1994) and for the detection of activin A in biological fluids and samples . The AS no. 64 antiserum detects monomeric and dimeric forms of activin A, and the cross-reactivity of AS no. 64 with monomeric A in the radioimmunoassay was estimated to be 17% (Robertson et al. 1992) . To test the specificity of the AS no. 64 staining, the antiserum was preabsorbed with human recombinant activin A. Preabsorption of the antiserum was achieved by incubating 5 µl undiluted antiserum with 1 µg human recombinant activin A in 200 µl PBS at 4 C overnight. The mixture was diluted to a total volume of 1 ml with PBS and centrifuged at 12 000 r.p.m., and the supernatant decanted and used accordingly.
An intact adult male New Zealand rabbit was used to raise the follistatin antiserum, AS no. 202, to purified bovine 39 kDa follistatin (Klein et al. 1991) . AS no. 202 detects 35, 39 and 45 kDa forms of follistatin and showed <0·5% cross-reactivity to bovine activin A or inhibin A. Preabsorption of the follistatin antiserum, to test the specificity of staining, was performed by incubating 5 µl antiserum with 1 µg purified bovine follistatins.
Immunolocalisation using cell lines For immunolocalisation, the cultured cells were plated onto a 96-well plate in concentrations of 5000 cells/well. Cells were then maintained in medium containing DMEM 5% CCS DHT (1 n) for 72 h. The medium was removed and cells washed once or twice in PBS. Cells were then fixed in Bouin's solution for 15 min at room temperature, washed once in 70% ethanol and stored at 4 C before immunocytochemistry. Immunocytochemistry was performed after the cells were washed three times in PBS and incubated with Triton X-100 (0·2%) for 15 min. In separate wells, the AS no. 64 (1:200) and the AS no. 202 (1:200) were incubated for 90 min at room temperature. The cells were washed three times and then incubated for 60 min with biotinylated rabbit anti-sheep IgG (1:200) for AS no. 64 and biotinylated sheep anti-rabbit IgG (1:200) for AS no. 202. Control wells were incubated with AS no. 64 preabsorbed with activin A or AS no. 202 preabsorbed with follistatin. Additional controls were also conducted using normal sheep serum and normal rabbit serum. After further washing with Tris-HCl buffer (pH 9·0), the cells were incubated with the enzyme complex, extravidin alkaline phosphatase (Sigma) for 60 min, and washed with Tris buffer. Colour development was carried out with New Fuchsin Substrate Kit (DAKO Corporation, CA, USA) and positive immunoreactivity was indicated by the presence of red/pink colour in the cells.
Detection of follistatin and C subunit mRNA expression by reverse transcription PCR Total RNA extraction Total RNA was extracted from adult rat testes, adult rat prostate, and 10 10 6 cultured cells as described by Chomczinsky & Sacchi (1987) . The tumour cells were cultured in DMEM +10% CCS and, in the case of the LNCaP cell line, with or without 1 n DHT.
Reverse transcription (RT) Standard reverse transcription was carried out using 2 µg total RNA, denatured at 65 C for 5 min, and mixed with 30 U reverse transcriptase (Promega Biotec, Madison, WI, USA), 40 U RNAsin (Promega Biotec), 15 pmol oligo (dT) 15 primer (Promega Biotec), 1 m each of dATP, dTTP, dCTP, dGTP (Promega Biotec), in 1 AMV reverse transcriptase buffer (Promega Biotec) to a final volume of 50 µl. The solution was incubated at 42 C for 2 h, heated to 95 C for 2 min and cooled rapidly on ice.
Polymerase chain reaction (PCR)
The PCR was performed in a Perkin Elmer Cetus DNA Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT, USA) as described by Saiki et al. (1985) . Briefly, 10 µl of the RT mixture was added to 0·2 m dNTP, 30 pmol of each primer, and 1 U of Ampli Taq DNA polymerase (Roche Molecular Systems Inc., Branchburg, NJ, USA) in PCR buffer (Roche Molecular Systems Inc.) in a final volume of 50 µl. Cycling conditions for the primers were as described previously (Schmitt et al. 1996 , Thomas et al. 1997 . PCR products were analysed by Nusieve GTG agarose gel electrophoresis in 1 TAE (0·04  Tris-acetate, 0·001  EDTA).
Automated sequence analysis (Micromon: Microbial Biotechnology and Diagnostic Unit, Monash University Department of Microbiology) of the RT-PCR-derived products from the cell lines confirmed the identity of the C subunit and follistatins. To further confirm the presence of both FS288 and FS315 mRNA species, follistatin sequences were subjected to Southern blot using a specific cDNA probe (Michel et al. 1990 ).
Probe labelling
The follistatin cDNA probe (Michel et al. 1990 ) was labelled by the following method. Briefly, 25 ng denatured probe was mixed with 1 hexanucleotide mix (Boehringer Mannheim GmbH Biochemica, Germany), 1 m each of dATP, dGTP, dTTP (Promega Biotec), 4 mCi 32 [P]dCTP (DuPont, NEN Research Products), and 10 U Klenow enzyme (Promega Biotec) in a final volume of 20 µl, and incubated overnight at room temperature. The probe was precipitated after the addition of 3 µg herring sperm DNA (Promega Biotec), 0·9  sodium perchlorate and 0·4 vol isopropanol in a final volume of 165 µl, and centrifuged at 13 000 g for 5 min. Labelling efficiency was determined by scintillation counting (1900 TR Liquid Scintillation Analyser, Packard Instrument Co., Groningen, The Netherlands).
[P] Southern blot analysis of RT-PCR products
Southern blot analysis of follistatin RT-PCR products was carried out as follows. Membranes were prehybridised for 1 h in Rapid Hyb buffer (Amersham Life Science, Bucks, UK), before addition of denatured probe. Hybridisation was carried out for 2 h before washing for 15 min, twice with 2 SSC+0·1% SDS, and twice with 0·5 SSC+0·1% SDS. The membranes were wrapped in plastic film, and autoradiography was carried out using XOMAT AR film (Eastman Kodak Co., NY, USA.) with intensifying screens at 75 C.
[ 3 H]Thymidine incorporation assay/DNA synthesis
A modified procedure based on that described by Wilding et al. (1989) was used. Briefly, cells were plated into 96-well plates (Falcon; Becton Dickinson Labware, Franklin Lakes, NJ, USA) in DMEM and 5% CCS. After 72 h, the media were replaced and appropriate test substances added to the subconfluent cultures of cells. Effects of growth substances were determined by the addition of [ 3 H]thymidine (0·5 µCi/ml) to wells for 20 h, after which cells were harvested and the incorporation of [
3 H]thymidine was determined by trichloroacetic acid precipitation and NaOH solubilisation. In each experiment, control wells containing appropriate buffer vehicle (0·1% TFN/ ACN or 0·1% DPBS+0·1% BSA or 50% glycerol, diluted in parallel) were included, corresponding with each ligand that was added. At time of harvest, cells were removed from wells set up in parallel by trypsinisation and counts were performed using an haemocytometer.
Statistical analyses
Analysis of data was conducted by one-way analysis of variance, after checking for normality and equal variance, using Sigmastat software ( Jandel Corporation, San Rafael, CA, USA). Determination of significance was based on means of at least five replicates and minimum significances (P<0·05) were calculated.
Results
Effect of activin A and B on LNCaP, DU145 and PC3 prostate tumour cell lines
Activin A and activin B significantly inhibited the incorporation of [ 3 H]thymidine by LNCaP cells compared with controls, when added to quiescent cells in the presence of 5% CCS at a dose of 40 ng/ml. These inhibitory responses were also observed in the presence of a stimulatory dose of androgen (1 n DHT), demonstrating that both activin A and B could overcome the additional stimulatory response to DHT. The degree of inhibition of the activin B was less than that of activin A used at the same dose, but limited availability of the activin B ligand prevented more extensive dose-response studies (Table 1) . Similarly, activins A and B each inhibited the uptake of [ 3 H]thymidine by DU145 tumour cells, the degree of inhibition being similar for both ligands. No effect of activin A or B was recorded on PC3 cells (Table 1) .
The dose-response effects of activin A on the androgenresponsive LNCaP cells ( 1 n DHT) and androgenindependent DU145 cell line are shown in Fig. 1 . In the absence of androgen, the LNCaP cell response could be inhibited by 8 pg/ml activin A (Fig. 1A) and a similar degree of inhibition of DNA synthesis (25% vs 27% inhibition, respectively) was observed in the presence of DHT (1 n) (Fig. 1B) . In both conditions, the maximal suppression could be achieved with 8 ng/ml activin A (Fig. 1A and B) . DNA synthesis by DU145 cells was inhibited by activin A and maximal suppression was also achieved with 8 ng/ml (Fig. 1C) . No suppression was recorded at the lower dose of 8 pg/ml activin A, suggesting that the DU145 cells were less sensitive to the inhibitory effects of activin A. No significant effect of activin A on PC-3 cells was observed (Fig. 1D) .
Effects of follistatin and inhibin on the response to activin A
LNCaP cells Activin A reduced DNA synthesis to approximately 2% of that in controls (Table 1) ; however, human recombinant FS288 was able to block completely the in vitro response to activin A by LNCaP cells, in both the presence and the absence of DHT ( Fig. 2A and B) . A tenfold excess of FS288 (400 ng/ml) was required to prevent completely the inhibitory response to 40 ng/ml activin A. In contrast to FS288, inhibin A was not able to block completely the action of activin A (40 ng/ml) when added at 40 ng or 400 ng/ml (Fig. 2C) to LNCaP cells cultured in the absence of 1 n DHT. In the presence of androgen stimulation (1 n DHT), and equimolar inhibin A (40 ng/ml), DNA synthesis remained at 2% of that in controls. Although a tenfold excess of inhibin A (400 ng/ml) resulted in a weak antagonism of activin action, DNA synthesis remained at 8% of that in vehicle controls (Fig. 2D ), and it was not possible to block completely the inhibitory effect of 40 ng/ml activin A with this high dose of inhibin A.
DU145 cells
The addition of activin A (40 ng/ml) caused a small, but significant and consistent, inhibition of [ 3 H]thymidine uptake (Table 2) . Follistatin was able to block this response when added in tenfold excess to activin A. In contrast to this effect of follistatin, the small but significant inhibition by activin A was not reversed by the addition of inhibin A at either an equivalent concentration or tenfold excess (Table 2) . Therefore, using both LNCaP and DU145 cell lines, a similar pattern of response to follistatin (which blocked activin) and to inhibin (which failed to do so) was observed (Fig. 2, Table 2 ).
Effect of human recombinant FS288 and inhibin alone on LNCaP and DU145 cells
The addition of human recombinant FS288 alone did not have any significant effect on DNA synthesis in vitro by either LNCaP or DU145 prostate tumour cells at 160 or 400 ng/ml (Table 3) .
Human recombinant inhibin A did not alter the uptake of [ 3 H]thymidine by LNCaP cells at doses of up to 40 ng/ml in the presence or absence of DHT. However, when a higher dose (400 ng/ml) was added to the LNCaP cells, there was a significant inhibition of [ 3 H]thymidine incorporation compared with the buffer control (Table 3) . There was no effect of inhibin A (400 ng/ml) on DU145 cells. Figure 3 shows the detection of follistatin and C expression in the tumour cell lines. Figure 3A shows that the Southern blot analysis detected both mRNA forms of follistatin produced by the RT-PCR reaction. Follistatin 315 was detected in LNCaP, DU145 and PC3 cells (lanes a-d), and the expression was shown to be independent of androgens. Follistatin 288 mRNA was detected only in the PC3 cells (lane d). Figure 3B demonstrates the presence of a 290 bp RT-PCR product in all three cell lines (lanes a-d). Automated sequencing confirmed this to be C mRNA.
Detection of follistatin and C subunit mRNA expression in LNCaP, DU145 and PC3 cells
Immunolocalisation of activin A and follistatin to the LNCaP, DU145 and PC3 cell lines
All three cell lines showed a positive immunoreactivity for activin A using AS no. 64 that was removed when the antiserum was preabsorbed with human recombinant activin A (Fig. 4) . Similarly, follistatin immunoreactivity localised to the cytoplasm of all three tumour cell lines using AS no. 202, whereas no staining was observed when the antiserum was preabsorbed with follistatin.
Discussion
This study has demonstrated the growth-inhibitory response by LNCaP and DU145 cells to activin A and B. This action can be blocked completely by the addition of follistatin. The capacity to synthesise activins and follistatins is demonstrated by the expression of follistatin mRNA and the localisation of activin and follistatin immunoreactivity to the tumour cells. These data demonstrate an action of activins A and B on human prostate tumour cells, and that the interplay between activins and follistatins is important in the regulation of growth of human prostate tumour cells.
There were differential responses to activin A by the three tumour cell lines. The level of inhibition by activin A and activin B on LNCaP cells was significantly greater than that which occurred on DU145 cells; there was no inhibitory effect of activin A or B on the PC3 cells. The inhibitory response to activin A was independent of androgens and was observed in the LNCaP cells cultured in the absence or presence of 1 n DHT and in the DU145 cells which are not responsive to androgens in Figure 2 The effect of follistatin or inhibin A, in combination with activin A, on DNA synthesis by LNCaP tumour cells. LNCaP cells were plated and cultured in media+5% CCS and the media replenished on day 3 with DMEM+5% CCS DHT (1 nM). In combination, activin A (actA) and human recombinant FS288 were added at ratios of 1:1 (40 ng/ml), 1:4 (40 ng/ml activin:160 ng/ml FS288), or 1:10 (40 ng/ml activin:400 ng/ml FS288) in the absence (A) and presence (B) of DHT. Control wells contained DMEM+5% CCS DHT (1 nM); vehicle wells contained a combined dose of activin vehicle (equivalent to 40 ng/ml activin A) and a dose of FS288 vehicle equivalent to 400 ng/ml. In combination, activin A (act) or inhibin A (inh) were added at ratios of 1:1 (40 ng/ml), or 1:10 (40 ng/ml activin:400 ng/ml inhibin) in the absence (C) and presence (D) of DHT. Control wells contained DMEM+5% CCS; vehicle wells contained a combined dose of activin vehicle and a dose of inhibin A vehicle equivalent to 400 ng/ml. Groups with the same superscripts are not significantly different. Different superscripts are significant (P<0·05). Each value represents the mean S.D. from five replicate wells.
vitro. Thus the apparent difference in activin A sensitivity is not related to a dependence upon androgens for tumour cell growth. The mechanism by which this inhibition occurs has not been explored in this study, but it is known that, in other tissues, activin A has antiproliferative effects in vitro (Gonzalez-Manchon & Vale 1989) and it has been shown to induce apoptosis in a hybridoma cell line (Nishihara et al. 1993) .
Although only the LNCaP and DU145 cells respond to activin A, all three cell lines are known to express mRNA for the A and B subunits (Batres et al. 1995 , Furst et al. 1995 . Our study localised activin A immunoreactivity to the cultured cells using a specific antiserum to dimeric activin A, and confirmed that endogenous production of activin A occurs in these cells. However, we were unable to detect and measure the synthesis of activin A secreted into the media or in cell lysates, using a specific radioimmunoassay employing the same antibody AS no. 64 . This observation might be due to activin A production that is below the limit of detection in the current activin assay . The immunoassay used for the measurement of activin A is not subject to interference from follistatin, therefore such interference is not the reason why activin A levels remain undetectable. It is possible that the synthesis or processing of the activin subunits may be altered, and that this may account for the undetectable levels of activin A. Mason et al. (1996) reported that high molecular weight forms of activins were biologically inactive when used in the serum-free rat pituitary cell bioassay. Alternatively, the putative activin C subunit mRNA (Hotten et al. 1995 ) is expressed by all of the tumour cells, suggesting that the potential to synthesise novel homo-and heterodimers of the activin subunits exists in these cells. The cross reaction of the novel activins formed by interaction with the C subunits and AS no. 64 is unknown. Whatever forms of activin are produced by these cells, there was no effect of exogenously added follistatin or inhibin A, and DNA synthesis was unaltered in LNCaP and DU145 cells -that is, the effect of endogenous activin ligand activity was not altered by exogenously added follistatin or inhibin A.
The expression and localisation of activin A to these cell lines and the demonstration that both activin A and activin B can inhibit cell proliferation by the LNCaP and DU145 tumour cells appear to contrast with the malignant characteristics of the tumour cell lines, which include rapid growth and proliferation. However, we have also shown that the activin-binding protein, follistatin, can completely block the action of activin A on the LNCaP and DU145 cells. Follistatin mRNA is expressed in all three tumour cell lines and follistatin immunoreactivity is localised to the cytoplasm of the cells using a specific antiserum, AS no. 202. The levels of follistatin produced by these cell lines were not measured and it is possible that the relative level of its production by the cells may contribute to their differential responses to exogenously added activin A or B. If the level of production of follistatin by the PC3 cells is higher than that by the LNCaP and DU145 cells, then this may account for the failure to respond to exogenously added activin A. Further measurement and comparison of the relative levels of follistatin synthesised or secreted by the three human prostate tumour cell lines remains to be made.
The colocalisation of follistatin and activin A to the tumour cells suggests that endogenously produced follistatin neutralises the inhibitory effect of endogenously produced activins. Alternatively, the exact form of follistatin produced by each cell line may be different and contribute to the differential responses to activin A. A number of follistatin proteins are known to exist, and at least nine molecular weight forms of follistatin have been described (Inouye et al. 1991 , Sugino et al. 1993 . These are derived from a single gene, which gives rise to three separate core proteins arising from two alternatively spliced mRNAs; these proteins are then mono-or di-glycosylated. It has been reported that the different molecular weight forms have variable potency -for example, in the suppression of FSH (Sugino et al. 1993 , Sumitomo et al. 1995 -and may also have variable effects in terms of neutralising activin bioactivity. The antiserum used for the detection of follistatin in the current study is known to detect some, but not all, forms of follistatin, namely the 35, 39 and 45 kDa molecular weight forms (Klein et al. 1991) . However, it is important to note that the PC3 cell line was shown to express both forms of mRNA for follistatin, implying that additional forms may be synthesised or secreted by the PC3 cells, whereas the DU145 and LNCaP cells only expressed FS315 mRNA. As the PC3 cells were unresponsive to activin A, this may be a significant observation in support of the hypothesis that different forms of follistatin have different roles in the regulation of activin A action in prostate tumour cells.
In contrast to follistatin, inhibin was unable to block completely the effect of activin A on LNCaP and DU145 tumour cells, even when added in tenfold excess to activin A. Dual opposing effects of inhibin and activin have been reported on primary cultures of testicular cells (Hsueh et al. 1987) , but inhibin does not antagonise the inhibitory effect of activin A on the proliferation of R2C Leydig tumour cells, and therefore it cannot be assumed that inhibin will always oppose the action of activin and vice versa. The effect of inhibin itself, at high doses (400 ng/ml), is inhibitory and is therefore similar, rather than opposite, to that of activin A. The reason why this high dose of inhibin has an effect similar to that of activin A is not known. It is possible that the inhibin preparation of 400 ng/ml contains a low level of activin A. In order to achieve the same degree of inhibition of DNA synthesis by LNCaP cells, 0·8-8 ng/ml activin would be required to be present in the 400 ng/ml inhibin preparation; this would represent a contamination of 0·2-2%.
We have recently reported inhibin immunoreactivity and subunit mRNA in rat ventral prostate and in patients with benign prostatic hyperplasia (Thomas et al. 1997) ; however, inhibin mRNA and protein were not detected in the LNCaP, DU145 or PC3 cell lines (Batres et al. 1995 , Furst et al. 1995 . A role for inhibins in tumour suppression was proposed as a result of the demonstration that inhibindeficient mice developed gonadal tumours (Matzuk et al. 1992) . Although the absence of the subunit gene in the prostate tumour cell lines is consistent with these latter observations, they contrast with the measurement of elevated serum levels in patients with granulosa cell tumours of the ovary (Healy et al. 1993) . Furthermore, the failure of inhibin to antagonise the effect of activin A would not support the hypothesis that inhibin subunit has a tumour-suppressive role in the cell lines.
In summary, this study has provided evidence that there is a differential response to activin A and B by the human prostate tumour cell lines LNCaP, DU145 and PC3. A growth-inhibitory effect of the LNCaP and DU145 cells, but not of the PC3 cell line, was observed . The inhibition was completely blocked by follistatin, but not by inhibin; as follistatin is present in the cell lines, we propose that the interaction between activin and follistatin, rather than between activin and inhibin, is important in the regulation of human prostate tumour cell growth.
